Estrogen Pretreatment Prior to GnRH Antagonist Protocol
NCT ID: NCT01489852
Last Updated: 2011-12-12
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE4
472 participants
INTERVENTIONAL
2006-12-31
2011-05-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Estrogen pre-treatment
17beta-estradiol
Pretreatment with 17beta-estradiol (Provames®, Aventis, Paris, France) was administered daily (2 mg twice a day) during the cycle preceding the IVF/ICSI cycle, starting 7 days before the predicted onset of menses and administered up until to the following Thursday after the occurrence of menses.
Control
The control group did not receive any pre-treatment.
No interventions assigned to this group
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
17beta-estradiol
Pretreatment with 17beta-estradiol (Provames®, Aventis, Paris, France) was administered daily (2 mg twice a day) during the cycle preceding the IVF/ICSI cycle, starting 7 days before the predicted onset of menses and administered up until to the following Thursday after the occurrence of menses.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* age \< 38 years,
* body mass index (BMI) between 18 and 30
* first or second IVF/ICSI attempt
Exclusion Criteria
* less than 5 follicles at the antral follicular count performed on day 3 of a spontaneous cycle,
* history of high (\>20 oocytes) or low (\< 5 oocytes) ovarian response in a previous IVF attempt
18 Years
38 Years
FEMALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Gemer
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Dr CEDRIN-DURNERIN Isabelle
principal investigator
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Jean Noel Hugues, MD, PhD
Role: STUDY_DIRECTOR
Hôpital Jean Verdier
Isabelle cedrin-durnerin, MD
Role: PRINCIPAL_INVESTIGATOR
Hôpital Jean Verdier
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Service de Medecine de la Reproduction, Hôpital Jean Verdier
Bondy, Île-de-France Region, France
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Cedrin-Durnerin I, Guivarc'h-Leveque A, Hugues JN; Groupe d'Etude en Medecine et Endocrinologie de la Reproduction. Pretreatment with estrogen does not affect IVF-ICSI cycle outcome compared with no pretreatment in GnRH antagonist protocol: a prospective randomized trial. Fertil Steril. 2012 Jun;97(6):1359-64.e1. doi: 10.1016/j.fertnstert.2012.02.028. Epub 2012 Mar 28.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
E2PRETREATMENT
Identifier Type: -
Identifier Source: org_study_id